Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4-9 positive lymph nodes

M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. M. Glas, S. Guerin, F. Cardoso, M. Piccart, T. Tursz, S. Delaloge, L. van't Veer

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The 70 gene-signature (MammaPrint®) is a prognostic profile of distant recurrence and survival of primary breast cancer (BC). BC patients with 4-9 positive nodes (LN 4-9) are considered clinically at high-risk. Herein we examined MammaPrint® added prognostic value in this group. Patients and methods: MammaPrint® profiles were generated from frozen tumours of patients operated from primary BC. Samples were classified as genomic Low Risk (GLR) or genomic High Risk (GHR). Results: Among the 173 samples, 70 (40%) were classified as GLR and 103 (60%) as GHR. Tumours in the GHR group were significantly more often ductal carcinomas (93%), grade 3 (60%), oestrogen and progesterone-negative, Her2 positive (25%). In the GLR category, the 5-year overall survival was 97% vs. 76% for in the GHR group ( p® is an independent prognostic marker in BC patients with LN 4-9 and may be integrated in a selection strategy of patients candidate for more aggressive therapeutic approaches.

Original languageEnglish
Pages (from-to)682-690
Number of pages9
JournalBreast
Volume22
Issue number5
DOIs
Publication statusPublished - Oct 2013

Keywords

  • 4-9 Positive nodes
  • Breast
  • Cancer
  • Genomic
  • High risk
  • Prognostic

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4-9 positive lymph nodes'. Together they form a unique fingerprint.

Cite this